BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Pernix Therapeutics, Inc. (PTX)’ Subsidiary Macoven Pharmaceuticals, LLC Named in Suit by Merck, Pamlab LLC and Others for Alleged Patent Violations


3/7/2012 6:16:51 AM

TYLER, Texas--(BUSINESS WIRE)--U.S. District Court for the Eastern District of Texas, three plaintiffs filed a complaint against four defendants, including Macoven Pharmaceuticals, owned by Pernix Therapeutics (PTX), alleging infringement of six patents. The other three defendants are Gnosis, S.p.A., Gnosis U.S.A and Gnosis Bioresearch SA (collectively “Gnosis”).

The Plaintiffs are: Merck & Cie, based in Switzerland; South Alabama Medical Science Foundation of Alabama (“SAMSF”); and Pamlab, LLC of Louisiana. According to the Complaint, SAMSF, a not-for-profit research organization, is the owner of five of the asserted patents. These five patents are exclusively licensed to Merck & Cie by SAMSF. Merck & Cie owns the remaining patent. Merck & Cie exclusively licenses these patents, in certain fields of use, to Pamlab. The asserted patents include: United States Patent Nos: 5,997,915; 6,011,040; 6,254,904; 6,673,381; 7,674,490 and 7,172,778.

Plaintiffs in the case state that Pamlab, LLC imports Metafolin® from Merck & Cie for use in its medical food products. Metafolin® is a highly specialized form of folate, which is an essential human nutrient. Metafolin® is used in dietary supplements, medical foods, nutritional supplements, pregnancy vitamins and foods for special dietary use. According to the Complaint, Pamlab uses Metafolin® in several of its pharmaceutical products including, Neevo DHA®, Metanx®, Cerefolin NAC®, and Deplin®.

The Plaintiffs allege that Macoven (a Pernix subsidiary) is now marketing a series of products that infringe Merck’s and SAMSF’S patents. The Macoven products named in the suit are: Vitaciric-B, ALZ-NAC, PNV DHA, and L-methylfolate Calcium 7.5mg and 15mg.

Plaintiffs have asked for an unspecified amount of damages as well as treble damages from Macoven. They also seek an injunction preventing Macoven from selling or distributing its infringing products, and attorney’s fees.

Macoven Pharmaceuticals is a wholly owned subsidiary of Pernix Therapeutics Holdings, Inc. which is based in The Woodlands, Texas and listed on the NYSE Amex (PTX).

Civil Action Number: 6:12-cv-00027

Contact:

Pamlab, LLC Legal Counsel (LA)

Keith Daigle, 985-893-4097

Legal Counsel

kdaigle@pamlab.com

or

South Alabama Medical Science foundation (AL)

Alston& Bird, LLP

Thomas J. Parker, 214-922-3437

Legal Counsel

thomas.parker@alston.com


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->